目的观察胰激肽原酶联合重组牛碱性成纤维细胞生长因子治疗糖尿病足患者的效果。方法选取2014年3月至2016年3月糖尿病足患者90例,将其随机分为两组,每组45例。对照组给予常规治疗,观察组在常规治疗基础上给予胰激肽原酶联合重组牛碱性成纤维细胞生长因子治疗。对比分析两组临床疗效及创面愈合情况。结果对照组治疗总有效率为75.6%,明显低于观察组的95.6%,差异有统计学意义(P<0.05);两组原创面积比较差异未见统计学意义(P>0.05);对照组治疗创面愈合时间、2周后创面面积、皮肤开始生长时间均明显优于观察组,差异有统计学意义(P<0.05)。结论胰激肽原酶联合重组牛碱性成纤维细胞生长因子治疗糖尿病足患者效果显著,可明显促进足部创面愈合的速度,缩短康复时间,且操作简便。 Objective To observe the effect of pancreatic kininogenase combined with recombinant bovine basic fibroblast growth factor in patients with diabetic foot. Methods 90 patients with diabetic foot from March 2014 to March 2016 were selected and randomly divided into two groups, 45 cases in each group. The control group was given routine treatment. The observation group was treated with pancreatic kallikrein combined with recombinant bovine basic fibroblast growth factor on the basis of routine treatment. The clinical efficacy and wound healing of the two groups were compared and analyzed. Results The total effective rate of the control group was 75.6%, which was significantly lower than that of the observation group (95.6%), the difference was statistically significant (P <0.05); the original area of ​​the two groups had no significant difference (P> 0.05) The wound healing time, the area of ​​wounds after 2 weeks, and the start of skin growth were significantly better than the observation group (P <0.05). Conclusions Pancreatic kallikrein combined with recombinant bovine basic fibroblast growth factor is effective in treating patients with diabetic foot. It can significantly accelerate the healing of foot wound and shorten the recovery time, and is easy to operate.